Search Results
Your search for ,are matches 21909 pages
Showing 1 - 50ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins). Results from the phase III...
Behind the Scenes of the 2026 ASCO Annual Meeting
The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues, and more. The 2026 meeting is expected to showcase paradigm-shifting science, presentations from...
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
Local radiotherapy may help control disease spread in patients with oligometastatic breast cancer, according to findings from the OLIGOMA trial presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 5611). “Currently, patients with oligometastatic ...
TAILORx and RxPONDER Trials Shift to a Discovery Platform
The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials. Through the translational study EA1241, researchers will...
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in...
Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma
CB-011, the first allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy incorporating immune cloaking, achieved a high overall response rate in heavily pretreated patients with relapsed or refractory multiple myeloma in the phase I CaMMouflage trial. Dose-escalation results were...
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...
Early Breast Cancer: Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy?
Select patients with early-stage breast cancer who achieved exceptional responses to ablative radiation therapy and endocrine therapy were able to omit surgery without disease progression, according to findings from a prospective phase II trial presented during the Congress of the European Society...
Long-Term EORTC Trial Challenges Assumptions About Lymph Node Radiation Therapy in Breast Cancer
Final results from a landmark European Organisation for Research and Treatment of Cancer (EORTC) randomized trial with more than 20 years of follow-up have shown that irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes reduces breast cancer mortality but does not...
Better Together: The Case for True Physician-AP Partnership in Oncology
At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and ...
I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
A Timely Compendium for the Era of Precision Oncology
The pace at which precision oncology has evolved over the past 2 decades, from the early promise of the Human Genome Project to the clinical reality of CAR T-cell therapy, antibody drug conjugates, and AI-assisted decision support, has made it increasingly difficult for even the most engaged...
Using Artificial Intelligence to Prescribe Cancer Drugs and Perform Other Tasks
In a recent article in The ASCO Post, we discussed increasing use of artificial intelligence (AI) in oncology and how physician-complementing AI can empower oncologists to be even better at what they do.1The reason AI is needed is that increasingly many variables need to be considered in cancer...
Survival Among Patients Treated in Community Oncology Settings Compared With National Benchmarks From SEER Database
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) when treated at community oncology practices participating in the Flatiron Health Research Network had better or comparable survival compared with national benchmark survival estimates generated by the...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
ASCO Congratulates 2026 Special Award Recipients
ASCO and Conquer Cancer, the ASCO Foundation, are proud to celebrate a distinguished group of individuals at the 2026 ASCO Annual Meeting. The Society will present its highest honors to researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous ...
Four Ways AI Is Transforming Patient Care—and What Lies Ahead
During her Presidential address at the 2025 ASCO Annual Meeting, Robin T. Zon, MD, FACP, FASCO, assessed how artificial intelligence (AI) is driving knowledge into action in the field of oncology, and acknowledged that “we are now at the crossroads of long-imagined possibilities and actionable...
Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health
Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, and many countries have now implemented CT-based screening programs. In a perspective recently...
Weight Trajectories Associated With Obesity-Related Cancer Risk
Individuals who gain the highest amounts of weight in adulthood are at significantly greater risk for developing certain obesity-related cancers, according to findings from a pooled cohort study presented at the European Congress on Obesity 2026 (Abstract 0759; AD16.04). The findings were also...
Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer,1 the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research fellow in Hematology-Oncology at Penn Medicine and colleagues have proposed an unorthodox...
Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk
Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results presented in a poster and at a press briefing during the 2026 American Association for Cancer...
Uniting Science, Practice, and Purpose for Better Cancer Care
Growing up as an American in Mexico City, I couldn’t have grasped how that upbringing would eventually shape my professional identity. While a career in oncology was far from my mind then, that cross-cultural foundation deeply influenced my approach to medicine and my leadership as ASCO’s 62nd...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
In two complementary preclinical studies published in Blood, investigators reported that mezigdomide, a cereblon E3 ligase modulator, may help overcome T-cell dysfunction in multiple myeloma, thereby enhancing the activity of BCMA-directed CAR T-cell and bispecific T-cell engager therapies. These...
Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer
Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at...
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that...
Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer
Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results from a two-arm pilot randomized trial that will be presented by Marchetti at the 2026 ASCO Annual...
Early-Stage Breast Cancer: Losing Weight, Gaining Quality of Life
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial,...
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
In a phase I/II trial (RMC-6236-001) reported in The New England Journal of Medicine, Wolpin et al identified the safety profile of daraxonrasib and showed activity of the agent in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib (RMC-6236) ...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
An international research team has shown that a specific subtype of diffuse large B-cell lymphoma (DLBCL) is associated with higher mortality risk in women than in men. The study was led by the laboratory of Ari Melnick, MD, Director of the Josep Carreras Leukaemia Research Institute and the Gebroe ...
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecurrent prostate cancer. Study Details A literature search through May 2025 was performed to identify...
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?
A systematic review and meta-analysis published in JAMA Network Open found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers. According to Inoue et al, this association appeared to be particularly pronounced in non–small cell lung...
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline...
Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ...
New Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma
A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen). “The launch of JAYseq represents a meaningful step in oncology testing, one that allows physicians to make a more precise treatment...
Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults
In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United States in recent years. Study Details The population-based study used linked Surveillance...
